Loading stock data…
Pyxis Oncology (PYXS)
$2.86+0.09 (+3.25%)
After Hours$2.82-0.04 (-1.40%)· Last close Jun 29
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Pyxis Oncology, Inc. in the Healthcare sector is trading at $2.86 with a market capitalization of $106M. Wall Street consensus targets $7.00 (8 analysts), implying a +144.8% move over the next 12 months. The stock is currently 48% below its 52-week high of $5.55, remaining 23.8% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +144.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | — | $11.04M | $0↓ | $2.82M | $0 |
| Gross Profit | — | $8.65M | $0↓ | $2.82M | $0 |
| Operating Income | — | -$18.30M↑ | -$23.46M↓ | -$19.75M↑ | -$22.91M |
| Net Income | — | -$18.11M↑ | -$22.00M↓ | -$18.35M↑ | -$21.16M |
Peer Comparison
JNJUNHPFE
Fundamentals
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$105.80M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-109.46%
Volume
Today's trading volume
1.23M
Recent News
Analysts See Nearly 3X Upside in Pyxis Oncology (PYXS)
While Pyxis Oncology, Inc. (NASDAQ:PYXS) has gained 54.78% year-to-date, analysts continue to see 293.30% upside, helping it secure a spot on our list of hot biotech stocks under $5 to buy. That analyst conviction is rooted in a busy clinical calendar, with key data readouts from Pyxis Oncology, Inc. (NASDAQ:PYXS)’s lead program expected across the […]
Creative Global Technology Holdings And 2 Other Promising Penny Stocks
Over the last 7 days, the U.S. market has risen by 2.6%, and in the past year, it has climbed an impressive 26%, with earnings forecasted to grow by 17% annually. In such a robust market environment, identifying stocks with solid financials becomes crucial for investors seeking potential growth opportunities. Though often considered a relic of past trading days, penny stocks still hold relevance today as they offer affordability and growth potential when backed by strong fundamentals; this...
NanoViricides’ Measles Treatment Granted Orphan Drug Designation by FDA
By Karen Roman NanoViricides, Inc. (NYSE: NNVC) said the FDA granted “Orphan Drug Designation” (ODD) to its clinical-stage, antiviral drug NV-387 for the treatment of measles, giving the company seven years of market exclusivity after approval and access to tax credits, among other benefits. There is no approved drug to treat the disease and NV-387 […]
3 Penny Stocks With Market Caps Under $400M To Consider
The market has shown robust performance, rising 3.1% over the last week and 27% over the past year, with earnings expected to grow by 16% annually in the coming years. In light of these conditions, identifying stocks with solid financials can be crucial for investors looking to capitalize on both value and growth opportunities. Penny stocks, despite their somewhat outdated moniker, remain relevant as they often represent smaller or newer companies that can offer significant potential when...
3 Penny Stocks With Market Caps Over $50M To Watch
As February begins, major U.S. stock indexes have surged, with the Dow Jones Industrial Average adding 515 points and the S&P 500 nearing record highs. This optimistic start to the month highlights a market environment where investors are keenly exploring opportunities across various sectors. Though often seen as a relic of past trading days, penny stocks still represent significant growth potential, particularly when they come from smaller or newer companies with strong financial foundations.